AtaGenix Laboratories
High-Quality Custom Peptides • Advanced Modifications • Worldwide Delivery
Professional solid-phase peptide synthesis with years of expertise. We deliver high-quality peptides tailored to your specific research needs.
Specialized modification services for research applications including antibody development and functional studies.
Professional peptide-carrier protein conjugation services for immunization and antibody production.
| Service Details | Delivery Time | Deliverables | Pricing |
|---|---|---|---|
| Standard Peptides Up to 30 amino acids |
2 weeks | • Custom peptide • HPLC analysis report • MS verification report |
Request Quote |
| Extended Services Longer sequences & gram-scale |
Consultation required | • Custom peptide • HPLC analysis report • MS verification report |
With over a decade of experience in solid-phase peptide synthesis, we provide reliable, high-quality peptides for research institutions, pharmaceutical companies, and biotechnology firms worldwide. Our state-of-the-art facilities ensure consistent quality and fast delivery times.
Get professional peptide synthesis services tailored to your research needs. Our experts are ready to help you achieve your scientific goals.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
AtaGenix provides highly specific anti-tauN368 monoclonal antibodies to support Alzheimer’s disease research using the hTau368 transgenic mouse model. These antibodies enable precise detection of truncated tau fragments in Western blot and immunofluorescence experiments, validating tau accumulation, phosphorylation, and associated cognitive deficits in the hippocampus. With exceptional specificity and stability, AtaGenix’s solutions empower researchers to explore tau pathology mechanisms and advance tau-targeted therapeutic development.